George Cardoza Sells 2,413 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CFO George Cardoza sold 2,413 shares on April 7 at an average price of $4.88 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, trimming his stake by 0.82% but leaving him with 292,861 shares (~$1.43M).
• SOPH shares traded around $4.89 (down ~0.3%) with a market cap of ~$335M, and the company reported a quarterly EPS loss of ($0.28) that missed estimates and showed a negative net margin (~44%); Wall Street’s consensus target is $7.00 amid mixed analyst ratings (two Buys, one Sell).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CFO George Cardoza sold 2,413 shares of SOPHiA GENETICS stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $4.88, for a total transaction of $11,775.44. Following the completion of the transaction, the chief financial officer owned 292,861 shares in the company, valued at approximately $1,429,161.68. This trade represents a 0.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Monday, April 6th, George Cardoza sold 2,520 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,222.00.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $3,707.46.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH traded down $0.01 during mid-day trading on Wednesday, reaching $4.89. The company had a trading volume of 64,929 shares, compared to its average volume of 188,371. The stock has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The firm has a fifty day simple moving average of $4.78 and a 200-day simple moving average of $4.68. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds have recently made changes to their positions in SOPH. Savvy Advisors Inc. purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $49,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research reports. Guggenheim raised their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. BTIG Research reissued a "buy" rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.